NCT06790212View on ClinicalTrials.gov

Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

August 30, 2027

Study Completion Date

June 30, 2028

Conditions

Colon Cancer

Interventions

DRUG

Ivonescimab

20mg/kg Q3W，D1

DRUG

Oxaliplatin

Oxaliplatin，130mg/m2，D1，Q3W；

DRUG

Capecitabine

Capecitabine，1000mg/m2，po，BID，D1-D14，Q3W

All Listed Sponsors

lead

Sun Yat-sen University

OTHER